中国组织工程研究 ›› 2017, Vol. 21 ›› Issue (19): 3063-3071.doi: 10.3969/j.issn.2095-4344.2017.19.018
• 骨与关节综述 bone and joint review • 上一篇 下一篇
梁 航,邓享誉,邵增务
出版日期:
2017-07-08
发布日期:
2017-08-10
通讯作者:
邵增务,博士,教授,博士生导师,华中科技大学同济医学院附属协和医院骨科医院,湖北省武汉市 430022
作者简介:
梁航,男,1992年生,河南省郑州市人,汉族,2015年苏州大学医学部毕业。
基金资助:
科技部国家重点研发计划(基于天然细胞外基质的系列智能凝胶原位诱导非骨组织再生的机制及理论研究),基金号:2016YFC1100100
Liang Hang, Deng Xiang-yu, Shao Zeng-wu
Online:
2017-07-08
Published:
2017-08-10
Contact:
Shao Zeng-wu, M.D., Professor, Doctoral supervisor, Orthopedic Hospital of Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China
About author:
Liang Hang, Orthopedic Hospital of Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China
Supported by:
the National Key Research and Development Program of Ministry of Science and Technology, No. 2016YFC1100100
摘要:
文题释义:
结果与结论:①干细胞移植的生物学修复技术为椎间盘退行性疾病提供新的治疗策略,迄今已在大量体外实验及动物模型中开展研究,并逐渐跨越至临床试验阶段,均取得显著成果;②然而,如何使干细胞移植后适应退变椎间盘的微环境、选择何种干细胞、如何掌握治疗的适应证等一系列问题对研究人员提出巨大挑战。 中国组织工程研究杂志出版内容重点:人工关节;骨植入物;脊柱;骨折;内固定;数字化骨科;组织工程 ORCID: 0000-0001-8299-4456(梁航)
中图分类号:
梁 航,邓享誉,邵增务. 干细胞技术用于椎间盘再生的研究进展及挑战[J]. 中国组织工程研究, 2017, 21(19): 3063-3071.
Liang Hang, Deng Xiang-yu, Shao Zeng-wu. Research progress and challenge of the stem cell therapy for intervertebral disc regeneration [J]. Chinese Journal of Tissue Engineering Research, 2017, 21(19): 3063-3071.
[1] Ivanova JI, Birnbaum HG, Schiller M, et al. Real-world practice patterns, health-care utilization, and costs in patients with low back pain: the long road to guideline-concordant care. Spine J. 2011;11(7): 622-632.[2] Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859): 2163-2196.[3] Kepler CK, Ponnappan RK, Tannoury CA, et al. The molecular basis of intervertebral disc degeneration. Spine J. 2013;13(3): 318-330.[4] Isgro M, Buraschi R, Barbieri C, et al. Conservative management of degenerative disorders of the spine. J Neurosurg Sci. 2014;58(2 Suppl 1): 73-76.[5] Miller SM. Low back pain: pharmacologic management. Prim Care. 2012;39(3): 499-510.[6] Wang MY, Vasudevan R, Mindea SA. Minimally invasive lateral interbody fusion for the treatment of rostral adjacent-segment lumbar degenerative stenosis without supplemental pedicle screw fixation. J Neurosurg Spine. 2014;21(6): 861-866.[7] Walsh AJ, Bradford DS, Lotz JC. In vivo growth factor treatment of degenerated intervertebral discs. Spine (Phila Pa 1976). 2004;29(2): 156-163.[8] Osada R, Ohshima H, Ishihara H, et al. Autocrine/paracrine mechanism of insulin-like growth factor-1 secretion, and the effect of insulin-like growth factor-1 on proteoglycan synthesis in bovine intervertebral discs. J Orthop Res. 1996;14(5): 690-699.[9] Imai Y, Okuma M, An HS, et al. Restoration of disc height loss by recombinant human osteogenic protein-1 injection into intervertebral discs undergoing degeneration induced by an intradiscal injection of chondroitinase ABC. Spine (Phila Pa 1976). 2007;32(11): 1197-1205.[10] Wei A, Williams LA, Bhargav D, et al. BMP13 prevents the effects of annular injury in an ovine model. Int J Biol Sci. 2009;5(5): 388-396.[11] An HS, Takegami K, Kamada H, et al. Intradiscal administration of osteogenic protein-1 increases intervertebral disc height and proteoglycan content in the nucleus pulposus in normal adolescent rabbits. Spine (Phila Pa 1976). 2005;30(1): 25-31; discussion 31-32.[12] Le Maitre CL, Freemont AJ, Hoyland JA. A preliminary in vitro study into the use of IL-1Ra gene therapy for the inhibition of intervertebral disc degeneration. Int J Exp Pathol. 2006;87(1): 17-28.[13] Le Maitre CL, Hoyland JA, Freemont AJ. Interleukin-1 receptor antagonist delivered directly and by gene therapy inhibits matrix degradation in the intact degenerate human intervertebral disc: an in situ zymographic and gene therapy study. Arthritis Res Ther. 2007; 9(4): R83.[14] Tobinick EL, Britschgi-Davoodifar S. Perispinal TNF-alpha inhibition for discogenic pain. Swiss Med Wkly. 2003;133 (11-12): 170-177.[15] Larson JW, Levicoff EA, Gilbertson LG, et al. Biologic modification of animal models of intervertebral disc degeneration. J Bone Joint Surg Am. 2006;88 Suppl 2: 83-87.[16] Acosta FL Jr, Lotz J, Ames CP. The potential role of mesenchymal stem cell therapy for intervertebral disc degeneration: a critical overview. Neurosurg Focus. 2005; 19(3): E4.[17] Illien-Junger S, Gantenbein-Ritter B, Grad S, et al. The combined effects of limited nutrition and high-frequency loading on intervertebral discs with endplates. Spine (Phila Pa 1976). 2010; 35(19): 1744-1752.[18] Illien-Junger S, Pattappa G, Peroglio M, et al. Homing of mesenchymal stem cells in induced degenerative intervertebral discs in a whole organ culture system. Spine (Phila Pa 1976). 2012;37(22): 1865-1873.[19] Pattappa G, Eroglio M, Sakai D, et al. CCL5/RANTES is a key chemoattractant released by degenerative intervertebral discs in organ culture. Eur Cell Mater. 2014;27: 124-136.[20] Tzaan WC, Chen HC. Investigating the possibility of intervertebral disc regeneration induced by granulocyte colony stimulating factor-stimulated stem cells in rats. Adv Orthop. 2011;2011: 602089.[21] Sakai D, Nishimura K, Tanaka M, et al. Migration of bone marrow-derived cells for endogenous repair in a new tail-looping disc degeneration model in the mouse: a pilot study. Spine J. 2015;15(6): 1356-1365.[22] Nishimura K, Mochida J. Percutaneous reinsertion of the nucleus pulposus. An experimental study. Spine (Phila Pa 1976). 1998;23(14): 1531-1538; discussion 1539.[23] Gruber HE, Johnson TL, Leslie K, et al. Autologous intervertebral disc cell implantation: a model using Psammomys obesus, the sand rat. Spine (Phila Pa 1976). 2002;27(15): 1626-1633.[24] Okuma M, Mochida J, Nishimura K, et al. Reinsertion of stimulated nucleus pulposus cells retards intervertebral disc degeneration: an in vitro and in vivo experimental study. J Orthop Res. 2000;18(6): 988-997.[25] Nomura T, Mochida J, Okuma M, et al. Nucleus pulposus allograft retards intervertebral disc degeneration. Clin Orthop Relat Res. 2001;(389): 94-101.[26] Sato M, Asazuma T, Ishihara M, et al. An experimental study of the regeneration of the intervertebral disc with an allograft of cultured annulus fibrosus cells using a tissue-engineering method. Spine (Phila Pa 1976). 2003; 28(6): 548-553.[27] Watanabe K, Mochida J, Nomura T, et al. Effect of reinsertion of activated nucleus pulposus on disc degeneration: an experimental study on various types of collagen in degenerative discs. Connect Tissue Res. 2003;44(2): 104-108.[28] Bertram H, Kroeber M, Wang H, et al. Matrix-assisted cell transfer for intervertebral disc cell therapy. Biochem Biophys Res Commun. 2005;331(4): 1185-1192.[29] Iwashina T, Mochida J, Sakai D, et al. Feasibility of using a human nucleus pulposus cell line as a cell source in cell transplantation therapy for intervertebral disc degeneration. Spine (Phila Pa 1976). 2006; 31(11): 1177-1186.[30] Huang B, Zhuang Y, Li CQ, et al. Regeneration of the intervertebral disc with nucleus pulposus cell-seeded collagen II/hyaluronan/chondroitin-6-sulfate tri-copolymer constructs in a rabbit disc degeneration model. Spine (Phila Pa 1976). 2011;36(26): 2252-2259.[31] Ganey T, Libera J, Moos V, et al. Disc chondrocyte transplantation in a canine model: a treatment for degenerated or damaged intervertebral disc. Spine (Phila Pa 1976). 2003;28(23): 2609-2620.[32] Ruan DK, Xin H, Zhang C, et al. Experimental intervertebral disc regeneration with tissue-engineered composite in a canine model. Tissue Eng Part A. 2010;16(7): 2381-2389.[33] Hohaus C, Ganey TM, Minkus Y, et al. Cell transplantation in lumbar spine disc degeneration disease. Eur Spine J. 2008; 17 Suppl 4: 492-503.[34] Mwale F, Roughley P, Antoniou J. Distinction between the extracellular matrix of the nucleus pulposus and hyaline cartilage: a requisite for tissue engineering of intervertebral disc. Eur Cell Mater. 2004;8: 58-63; discussion 63-64.[35] Vasiliadis ES, Pneumaticos SG, Evangelopoulos DS, et al. Biologic treatment of mild and moderate intervertebral disc degeneration. Mol Med. 2014;20: 400-409.[36] Carragee EJ, Don AS, Hurwitz EL, et al. 2009 ISSLS Prize Winner: Does discography cause accelerated progression of degeneration changes in the lumbar disc: a ten-year matched cohort study. Spine (Phila Pa 1976). 2009; 34(21): 2338-2345.[37] Nassr A, Lee JY, Bashir RS, et al. Does incorrect level needle localization during anterior cervical discectomy and fusion lead to accelerated disc degeneration? Spine (Phila Pa 1976). 2009;34(2): 189-192.[38] Chadderdon RC, Shimer AL, Gilbertson LG, et al. Advances in gene therapy for intervertebral disc degeneration. Spine J. 2004; 4(6 Suppl): 341S-347S.[39] Gruber HE, Ingram JA, Norton HJ, et al. Senescence in cells of the aging and degenerating intervertebral disc: immunolocalization of senescence-associated beta-galactosidase in human and sand rat discs. Spine (Phila Pa 1976). 2007;32(3): 321-327.[40] Roberts S, Evans EH, Kletsas D, et al. Senescence in human intervertebral discs. Eur Spine J. 2006;15 Suppl 3: S312-316.[41] Wang H, Zhou Y, Huang B, et al. Utilization of stem cells in alginate for nucleus pulposus tissue engineering. Tissue Eng Part A. 2014;20(5-6): 908-920.[42] Hiyama A, Mochida J, Iwashina T, et al. Transplantation of mesenchymal stem cells in a canine disc degeneration model. J Orthop Res. 2008;26(5): 589-600.[43] Feng G, Zhao X, Liu H, et al. Transplantation of mesenchymal stem cells and nucleus pulposus cells in a degenerative disc model in rabbits: a comparison of 2 cell types as potential candidates for disc regeneration. J Neurosurg Spine. 2011;14(3): 322-329.[44] Serigano K, Sakai D, Hiyama A, et al. Effect of cell number on mesenchymal stem cell transplantation in a canine disc degeneration model. J Orthop Res. 2010;28(10): 1267-1275.[45] Jin ES, Min J, Jeon SR, et al. Analysis of molecular expression in adipose tissue-derived mesenchymal stem cells : prospects for use in the treatment of intervertebral disc degeneration. J Korean Neurosurg Soc. 2013;53(4): 207-212.[46] Anderson DG, Markova D, An HS, et al. Human umbilical cord blood-derived mesenchymal stem cells in the cultured rabbit intervertebral disc: a novel cell source for disc repair. Am J Phys Med Rehabil. 2013;92(5): 420-429.[47] Chun HJ, Kim YS, Kim BK, et al. Transplantation of human adipose-derived stem cells in a rabbit model of traumatic degeneration of lumbar discs. World Neurosurg. 2012;78(3-4): 364-371.[48] Ganey T, Hutton WC, Moseley T, et al. Intervertebral disc repair using adipose tissue-derived stem and regenerative cells: experiments in a canine model. Spine (Phila Pa 1976). 2009;34(21): 2297-2304.[49] Allon AA, Aurouer N, Yoo BB, et al. Structured coculture of stem cells and disc cells prevent disc degeneration in a rat model. Spine J. 2010;10(12): 1089-1097.[50] Watanabe T, Sakai D, Yamamoto Y, et al. Human nucleus pulposus cells significantly enhanced biological properties in a coculture system with direct cell-to-cell contact with autologous mesenchymal stem cells. J Orthop Res. 2010; 28(5): 623-630.[51] Miyamoto T, Muneta T, Tabuchi T, et al. Intradiscal transplantation of synovial mesenchymal stem cells prevents intervertebral disc degeneration through suppression of matrix metalloproteinase-related genes in nucleus pulposus cells in rabbits. Arthritis Res Ther. 2010;12(6): R206.[52] Crevensten G, Walsh AJ, Ananthakrishnan D, et al. Intervertebral disc cell therapy for regeneration: mesenchymal stem cell implantation in rat intervertebral discs. Ann Biomed Eng. 2004;32(3): 430-434.[53] Pei M, Shoukry M, Li J, et al. Modulation of in vitro microenvironment facilitates synovium-derived stem cell-based nucleus pulposus tissue regeneration. Spine (Phila Pa 1976). 2012; 37(18): 1538-1547.[54] Longo UG, Papapietro N, Petrillo S, et al. Mesenchymal stem cell for prevention and management of intervertebral disc degeneration. Stem Cells Int. 2012;2012: 921053.[55] Liang CZ, Li H, Tao YQ, et al. Dual release of dexamethasone and TGF-beta3 from polymeric microspheres for stem cell matrix accumulation in a rat disc degeneration model. Acta Biomater. 2013;9(12): 9423-9433.[56] Murrell W, Sanford E, Anderberg L, et al. Olfactory stem cells can be induced to express chondrogenic phenotype in a rat intervertebral disc injury model. Spine J. 2009;9(7): 585-594.[57] Yim RL, Lee JT, Bow CH, et al. A systematic review of the safety and efficacy of mesenchymal stem cells for disc degeneration: insights and future directions for regenerative therapeutics. Stem Cells Dev. 2014;23(21): 2553-2567.[58] Minogue BM, Richardson SM, Zeef LA, et al. Characterization of the human nucleus pulposus cell phenotype and evaluation of novel marker gene expression to define adult stem cell differentiation. Arthritis Rheum. 2010;62(12): 3695-3705.[59] Jeong JH, Lee JH, Jin ES, et al. Regeneration of intervertebral discs in a rat disc degeneration model by implanted adipose-tissue-derived stromal cells. Acta Neurochir (Wien). 2010;152(10): 1771-1777.[60] Orozco L, Soler R, Morera C, et al. Intervertebral disc repair by autologous mesenchymal bone marrow cells: a pilot study. Transplantation. 2011;92(7): 822-828.[61] Vadala G, Sowa G, Hubert M, et al. Mesenchymal stem cells injection in degenerated intervertebral disc: cell leakage may induce osteophyte formation. J Tissue Eng Regen Med. 2012; 6(5): 348-355.[62] Sakai D, Mochida J, Yamamoto Y, et al. Transplantation of mesenchymal stem cells embedded in Atelocollagen gel to the intervertebral disc: a potential therapeutic model for disc degeneration. Biomaterials. 2003;24(20):3531-3541.[63] Yang H, Wu J, Liu J, et al. Transplanted mesenchymal stem cells with pure fibrinous gelatin-transforming growth factor-beta1 decrease rabbit intervertebral disc degeneration. Spine J. 2010;10(9): 802-810.[64] Leckie SK, Sowa GA, Bechara BP, et al. Injection of human umbilical tissue-derived cells into the nucleus pulposus alters the course of intervertebral disc degeneration in vivo. Spine J. 2013; 13(3): 263-272.[65] Subhan RA, Puvanan K, Murali MR, et al. Fluoroscopy assisted minimally invasive transplantation of allogenic mesenchymal stromal cells embedded in HyStem reduces the progression of nucleus pulposus degeneration in the damaged ntervertebral [corrected] disc: a preliminary study in rabbits. Scientific World J. 2014;2014: 818502.[66] Henriksson HB, Hagman M, Horn M, et al. Investigation of different cell types and gel carriers for cell-based intervertebral disc therapy, in vitro and in vivo studies. J Tissue Eng Regen Med. 2012;6(9): 738-747.[67] Ruan D, Xin H, Zhang C, et al. Experimental intervertebral disc regeneration with tissue-engineered composite in a canine model. Tissue Eng Part A. 2010;16(7): 2381-2389.[68] Yoshikawa T, Ueda Y, Miyazaki K, et al. Disc regeneration therapy using marrow mesenchymal cell transplantation: a report of two case studies. Spine (Phila Pa 1976). 2010; 35(11): E475-480.[69] Meisel HJ, Ganey T, Hutton WC, et al. Clinical experience in cell-based therapeutics: intervention and outcome. Eur Spine J. 2006;15 Suppl 3: S397-405.[70] Meisel HJ, Siodla V, Ganey T, et al. Clinical experience in cell-based therapeutics: disc chondrocyte transplantation A treatment for degenerated or damaged intervertebral disc. Biomol Eng. 2007;24(1): 5-21.[71] Coric D, Pettine K, Sumich A, et al. Prospective study of disc repair with allogeneic chondrocytes presented at the 2012 Joint Spine Section Meeting. J Neurosurg Spine. 2013;18(1): 85-95.[72] Brodin H. Paths of nutrition in articular cartilage and intervertebral discs. Acta Orthop Scand. 1955;24(3): 177-183.[73] Grunhagen T, Shirazi-Adl A, Fairbank JC, et al. Intervertebral disk nutrition: a review of factors influencing concentrations of nutrients and metabolites. Orthop Clin North Am. 2011;42(4): 465-477, vii.[74] Holm S, Maroudas A, Urban JP, et al. Nutrition of the intervertebral disc: solute transport and metabolism. Connect Tissue Res. 1981;8(2): 101-119.[75] Risbud MV, Shapiro IM. Role of cytokines in intervertebral disc degeneration: pain and disc content. Nat Rev Rheumatol. 2014; 10(1): 44-56.[76] Krock E, Rosenzweig DH, Haglund L. The Inflammatory Milieu of the Degenerate Disc: Is Mesenchymal Stem Cell-based Therapy for Intervertebral Disc Repair a Feasible Approach? Curr Stem Cell Res Ther. 2015;10(4): 317-328.[77] Wuertz K, Haglund L. Inflammatory mediators in intervertebral disk degeneration and discogenic pain. Global Spine J. 2013;3(3): 175-184.[78] Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411): 143-147.[79] Steck E, Bertram H, Abel R, et al. Induction of intervertebral disc-like cells from adult mesenchymal stem cells. Stem Cells. 2005;23(3): 403-411.[80] Risbud MV, Guttapalli A, Albert TJ, et al. Hypoxia activates MAPK activity in rat nucleus pulposus cells: regulation of integrin expression and cell survival. Spine (Phila Pa 1976). 2005; 30(22): 2503-2509.[81] Stoyanov JV, Gantenbein-Ritter B, Bertolo A, et al. Role of hypoxia and growth and differentiation factor-5 on differentiation of human mesenchymal stem cells towards intervertebral nucleus pulposus-like cells. Eur Cell Mater. 2011;21: 533-547.[82] Liang C, Li H, Tao Y, et al. Responses of human adipose-derived mesenchymal stem cells to chemical microenvironment of the intervertebral disc. J Transl Med. 2012;10: 49.[83] Wuertz K, Godburn K, Neidlinger-Wilke C, et al. Behavior of mesenchymal stem cells in the chemical microenvironment of the intervertebral disc. Spine (Phila Pa 1976). 2008;33(17): 1843-1849.[84] Orth P, Rey-Rico A, Venkatesan JK, et al. Current perspectives in stem cell research for knee cartilage repair. Stem Cells Cloning. 2014; 7: 1-17.[85] Matta C, Mobasheri A, Gergely P, et al. Ser/Thr-phosphoprotein phosphatases in chondrogenesis: neglected components of a two-player game. Cell Signal. 2014;26(10): 2175-2185.[86] Mennan C, Wright K, Bhattacharjee A, et al. Isolation and characterisation of mesenchymal stem cells from different regions of the human umbilical cord. Biomed Res Int. 2013; 2013: 916136.[87] Liu S, Hou KD, Yuan M, et al. Characteristics of mesenchymal stem cells derived from Wharton's jelly of human umbilical cord and for fabrication of non-scaffold tissue-engineered cartilage. J Biosci Bioeng. 2014;117(2): 229-235.[88] Patel AA, Spiker WR, Daubs M, et al. Evidence for an inherited predisposition to lumbar disc disease. J Bone Joint Surg Am. 2011;93(3): 225-229.[89] Fong CY, Chak LL, Biswas A, et al. Human Wharton's jelly stem cells have unique transcriptome profiles compared to human embryonic stem cells and other mesenchymal stem cells. Stem Cell Rev. 2011;7(1):1-16.[90] Harkness EF, Macfarlane GJ, Silman AJ, et al. Is musculoskeletal pain more common now than 40 years ago?: Two population-based cross-sectional studies. Rheumatology (Oxford). 2005;44(7):890-895.[91] La Rocca G, Lo Iacono M, Corsello T, et al. Human Wharton's jelly mesenchymal stem cells maintain the expression of key immunomodulatory molecules when subjected to osteogenic, adipogenic and chondrogenic differentiation in vitro: new perspectives for cellular therapy. Curr Stem Cell Res Ther. 2013;8(1):100-113.[92] Cornejo MC, Cho SK, Giannarelli C, et al. Soluble factors from the notochordal-rich intervertebral disc inhibit endothelial cell invasion and vessel formation in the presence and absence of pro-inflammatory cytokines. Osteoarthritis Cartilage. 2015;23(3):487-496.[93] de Vries SA, Potier E, van Doeselaar M, et al. Conditioned medium derived from notochordal cell-rich nucleus pulposus tissue stimulates matrix production by canine nucleus pulposus cells and bone marrow-derived stromal cells. Tissue Eng Part A. 2015;21(5-6): 1077-1084.[94] Hiyama A, Mochida J, Sakai D. Stem cell applications in intervertebral disc repair. Cell Mol Biol (Noisy-le-grand). 2008; 54(1): 24-32.[95] Paesold G, Nerlich AG, Boos N. Biological treatment strategies for disc degeneration: potentials and shortcomings. Eur Spine J. 2007;16(4): 447-468.[96] Purmessur D, Schek RM, Abbott RD, et al. Notochordal conditioned media from tissue increases proteoglycan accumulation and promotes a healthy nucleus pulposus phenotype in human mesenchymal stem cells. Arthritis Res Ther. 2011; 13(3): p. R81.[97] Stemper BD, Baisden JL, Yoganandan N, et al. Mechanical yield of the lumbar annulus: a possible contributor to instability: Laboratory investigation. J Neurosurg Spine. 2014; 21(4): 608-613.[98] Strassburg S, Richardson SM, Freemont AJ, et al. Co-culture induces mesenchymal stem cell differentiation and modulation of the degenerate human nucleus pulposus cell phenotype. Regen Med. 2010; 5(5): 701-711.[99] Yuan M, Yeung CW, Li YY, et al. Effects of nucleus pulposus cell-derived acellular matrix on the differentiation of mesenchymal stem cells. Biomaterials. 2013;34(16): 3948-3961.[100] Le Visage C, Kim SW, Tateno K, et al. Interaction of human mesenchymal stem cells with disc cells: changes in extracellular matrix biosynthesis. Spine (Phila Pa 1976). 2006;31(18): 2036-2042.[101] Sivakamasundari V, Lufkin T. Stemming the Degeneration: IVD Stem Cells and Stem Cell Regenerative Therapy for Degenerative Disc Disease. Adv Stem Cells. 2013;2013. pii: 724547.[102] Benneker LM, Andersson G, Iatridis JC, et al. Cell therapy for intervertebral disc repair: advancing cell therapy from bench to clinics. Eur Cell Mater. 2014;27: 5-11.[103] Sethe S, Scutt A, Stolzing A. Aging of mesenchymal stem cells. Ageing Res Rev. 2006; 5(1): 91-116.[104] McLain RF, Fleming JE, Boehm CA, et al. Aspiration of osteoprogenitor cells for augmenting spinal fusion: comparison of progenitor cell concentrations from the vertebral body and iliac crest. J Bone Joint Surg Am. 2005; 87(12): 2655-2661.[105] Gorensek M, Jaksimovic C, Kregar-Velikonja N, et al. Nucleus pulposus repair with cultured autologous elastic cartilage derived chondrocytes. Cell Mol Biol Lett. 2004;9(2): 363-373.[106] Liu Y, Rahaman MN, Bal BS. Modulating notochordal differentiation of human induced pluripotent stem cells using natural nucleus pulposus tissue matrix. PLoS One. 2014;9(7): e100885.[107] Sheikh H, Zakharian K, De La Torre RP, et al. In vivo intervertebral disc regeneration using stem cell-derived chondroprogenitors. J Neurosurg Spine. 2009;10(3): 265-272.[108] Malik KM, Cohen SP, Walega DR, et al. Diagnostic criteria and treatment of discogenic pain: a systematic review of recent clinical literature. Spine J. 2013;13(11): 1675-1689. |
[1] | 张皓博, 赵宇楠, 杨学军. 细胞焦亡在椎间盘退变中的作用及治疗意义[J]. 中国组织工程研究, 2022, 26(9): 1445-1451. |
[2] | 王 景, 熊 山, 曹 金, 冯林伟, 王 信. 白细胞介素3在骨代谢中的作用及机制[J]. 中国组织工程研究, 2022, 26(8): 1260-1265. |
[3] | 肖 豪, 刘 静, 周 君. 脉冲电磁场治疗绝经后骨质疏松症的研究进展[J]. 中国组织工程研究, 2022, 26(8): 1266-1271. |
[4] | 惠小珊, 白 京, 周思远, 王 阶, 张金生, 何庆勇, 孟培培. 中医药调控干细胞诱导分化的理论机制[J]. 中国组织工程研究, 2022, 26(7): 1125-1129. |
[5] | 安维政, 何 萧, 任 帅, 刘建宇. 肌源干细胞在周围神经再生中的潜力[J]. 中国组织工程研究, 2022, 26(7): 1130-1136. |
[6] | 范一鸣, 刘方煜, 张洪宇, 李 帅, 王岩松. 脊髓损伤后室管膜区内源性神经干细胞反应的系列问题[J]. 中国组织工程研究, 2022, 26(7): 1137-1142. |
[7] | 田 川, 朱向情, 杨再玲, 鄢东海, 李 晔, 王严影, 杨育坤, 何 洁, 吕冠柯, 蔡学敏, 舒丽萍, 何志旭, 潘兴华. 骨髓间充质干细胞调控猕猴卵巢的衰老[J]. 中国组织工程研究, 2022, 26(7): 985-991. |
[8] | 胡 伟, 谢兴奇, 屠冠军. 骨髓间充质干细胞来源外泌体改善脊髓损伤后血脊髓屏障的完整性[J]. 中国组织工程研究, 2022, 26(7): 992-998. |
[9] | 王新民, 刘 飞, 许 杰, 白玉玺, 吕 剑. 髓芯减压联合牙髓干细胞治疗兔早期激素性股骨头坏死[J]. 中国组织工程研究, 2022, 26(7): 1074-1079. |
[10] | 房晓磊, 冷 军, 张 晨, 刘会敏, 郭 文. 间充质干细胞不同移植途径治疗缺血性脑卒中疗效差异的系统评价[J]. 中国组织工程研究, 2022, 26(7): 1085-1092. |
[11] | 郭 嘉, 丁琼桦, 刘 泽, 吕思懿, 周泉程, 高玉花, 白春雨. 间充质干细胞来源外泌体的生物学特性及免疫调控作用[J]. 中国组织工程研究, 2022, 26(7): 1093-1101. |
[12] | 张璟琳, 冷 敏, 朱博恒, 汪 虹. 干细胞源外泌体促进糖尿病创面愈合的机制及应用[J]. 中国组织工程研究, 2022, 26(7): 1113-1118. |
[13] | 黄晨玮, 费彦亢, 朱梦梅, 李鹏昊, 于 兵. 谷胱甘肽在干细胞“干性”及调控中的重要作用[J]. 中国组织工程研究, 2022, 26(7): 1119-1124. |
[14] | 侯婧瑛, 郭天柱, 于萌蕾, 龙会宝, 吴 浩. 缺氧预处理通过激活MALAT1靶向抑制miR-195促进骨髓间充质干细胞的生存和血管形成[J]. 中国组织工程研究, 2022, 26(7): 1005-1011. |
[15] | 周 颖, 张 幻, 廖 松, 胡凡琦, 易 静, 刘玉斌, 靳继德. 去铁胺联合干扰素γ预处理对人牙髓干细胞的免疫调节作用[J]. 中国组织工程研究, 2022, 26(7): 1012-1019. |
1.1 资料来源
尽管椎间盘细胞移植治疗椎间盘退变的研究取得很好的前景,但是从自体获得可用的椎间盘细胞是非常困难的。一方面,选择健康的椎间盘提取细胞不仅会对其造成医源性损伤,而且在特殊的椎间盘微环境下,健康的椎间盘中有活力的细胞数量本身相对较少,如果从中获取细胞将会导致一系列并发症,加快健康椎间盘的退变。另一方面,选择突出或者脱出的退变的椎间盘提取细胞存在更大的限制,退变的椎间盘中健康的细胞数量进一步减少,从中提取的细胞常常表现为早衰,其细胞活性及增殖能力均下降,移植后的生存能力及功能性也会明显降低,不宜作为移植细胞的选择。因此,尽管自体椎间盘细胞移植在治疗椎间盘退变方面取得显著成果,但细胞来源的短缺或许将成为限制其发展的潜在因素。近年来,同种异体及异种来源的细胞被用于动物实验研究中,取得不错效果。但目前仍缺乏临床试验证据,同时受限于伦理道德问题,有待进一步深入研究。
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||